Program

Cancer Vaccine Conference
Amsterdam

International Meeting on Cancer Vaccines

Felix Meritis,
Keizersgracht 324, Amsterdam, The Netherlands
November 24-25, 2015
# Session 1: Vaccination strategies

**Chair:** Arjan Griffioen (Amsterdam, Netherlands)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.15-14.45</td>
<td>Cornelis Melief   (Leiden, The Netherlands)</td>
<td>Treatment of cancer by therapeutic vaccines requires combination treatment</td>
</tr>
<tr>
<td>14.45-15.15</td>
<td>Stéphane Ascarateil (Paris, France)</td>
<td>Characteristics of adjuvants for therapeutic cancer vaccines</td>
</tr>
<tr>
<td>15.15-15.30</td>
<td>Federica Ricardo (Turin, Italy)</td>
<td>DNA vaccination against human CSPG4 for the treatment of malignant melanoma: a comparative oncology trial in dogs</td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>Lena Kranz (Mainz, Germany)</td>
<td>A liposome-based vaccination platform for the treatment of cancer</td>
</tr>
<tr>
<td>16.00-16.30</td>
<td>Evelien Smits (Antwerp, Belgium)</td>
<td>Vaccination with WT1 mRNA-electroporated dendritic cells as postremission treatment can avoid or delay relapse in acute myeloid leukemia: phase II study with 30 patients</td>
</tr>
<tr>
<td>16.45-17.00</td>
<td>Rein Verbeke (Ghent, Belgium)</td>
<td>Immunogenic mRNA nanoparticles for dendritic cell-based cancer vaccination</td>
</tr>
<tr>
<td>17.00-18.00</td>
<td></td>
<td>Opening mixer</td>
</tr>
</tbody>
</table>
Wednesday Morning, November 25th, 2015

Session 2

Vaccination targeting the vasculature

Chair: Anna-Karin Olsson, (Uppsala, Sweden)

09.00-09.30 Michael Platten
(Heidelberg, Germany)
Immunotherapeutic options for brain tumors

09.30-10.00 Anna-Karin Olsson
(Uppsala Sweden)
Targeting tumor vessels by therapeutic vaccination

10.00-10.30 Lars Holmgren
(Stockholm, Sweden)
Targeting novel endothelial junction proteins in cancer

10.30-11.00 Coffee Break

11.00-11.30 Elisabeth Huijbers
(Amsterdam, The Netherlands)
The quest for targets in the tumor vasculature – enhanced vaccination strategies

11.30-12.00 Roy Bicknell
(Birmingham, UK)
Robo4 vaccines induce antibodies that retard tumor growth

12.00-12.30 Madelon Wentink
(Amsterdam, The Netherlands)
hVEGF26-104/RFASE: An angiostatic vaccine targeting VEGF

12.30-13.45 Lunch

Wednesday Afternoon, November 25th, 2015

Session 3

Promising targets and adjuvants

Chair: Michael Platten (Heidelberg, Germany)

13.45-14.15 Yvette van Kooyk
(Amsterdam, The Netherlands)
Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines.

14.15-14.45 Lars Hellman
(Uppsala, Sweden)
Vaccines targeting self-antigens:
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.15-15.45</td>
<td>Tea Break</td>
</tr>
<tr>
<td>15.45-16.15</td>
<td>Jolanda de Vries (Nijmegen, Netherlands) Harnessing adaptive immune responses in hereditary cancer</td>
</tr>
<tr>
<td>16.15-16.45</td>
<td>Tanja de Gruijl (Amsterdam, The Netherlands) Fighting local immune suppression – improving the odds for cancer vaccination</td>
</tr>
<tr>
<td>16.45-17.00</td>
<td>Sophie Dusoswa (Amsterdam, The Netherlands) Turning tumor glycans into anti-cancer vaccines</td>
</tr>
<tr>
<td>17.00-17.15</td>
<td>Julia Femel (Uppsala, Sweden) A therapeutic cancer vaccine against galectin-1</td>
</tr>
</tbody>
</table>